Treatment of rheumatoid arthritis with etanercept

被引：20

作者：

Genovese, MC

Kremer, JM

机构：

[1] Stanford Univ, Med Ctr, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA

[2] Ctr Rheumatol, Albany, NY 12203 USA

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2004年 / 30卷 / 02期

关键词：

D O I：

10.1016/j.rdc.2004.01.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Etanercept is effective in the treatment of rheumatoid arthritis (RA) when used as monotherapy and in combination with methotrexate (MTX). Radiographic progression of disease was slowed significantly when the drug was used for a 24-month period and was statistically significantly better than MTX. In addition to its use in RA, etanercept is approved by the U.S. Food and Drug Administration for other rheumatologic conditions, including psoriatic arthritis, ankylosing spondylitis, and juvenile chronic arthritis.

引用

页码：311 / +

页数：20

共 56 条

[1]

*AMG CORP, 2002, ENBR ET PRESCR INF

[2]

Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO

[3]

2-F

[4]

[Anonymous], 1999, Neurology, V53, P457

[5] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].

Bathon, JM ;

Martin, RW ;

Fleischmann, RM ;

Tesser, JR ;

Schiff, MH ;

Keystone, EC ;

Genovese, MC ;

Wasko, MC ;

Moreland, LW ;

Weaver, AL ;

Markenson, J ;

Finck, BK .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593

[6]

Bendele AM, 2000, ARTHRITIS RHEUM-US, V43, P2648, DOI 10.1002/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO

[7]

2-M

[8]

Breedveld F, 1998, EUR CYTOKINE NETW, V9, P233

[9] Rheumatoid arthritis and the risk of malignancy [J].

Cibere, J ;

Sibley, J ;

Haga, M .

ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1580-1586

[10]

DAVIS JC, 2003, ANN RHEUM DIS S1, V62

← 1 2 3 4 5 6 →